Nuvalent Inc Cl A NUVL

$123.36 -0.03 (-0.02%)

Valuation

Market cap
9,744,403,000
Revenue TTM
$0
Net income TTM
$-425,380,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
4,800,272
Avg volume
2,142,848
Day's range
$123.30 – $123.50
Shares out
78,998,000
Stochastic %K
99%
Beta
1.15
Analysts
Sell
Price target
$130.34

Price

Company profile

Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKI...

Show more

Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the Phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; Neladalkib (NVL-655), a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the Phase 2 portion of the ALKOVE-1 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR that is in Phase 1a/1b clinical trial. Nuvalent, Inc. has a strategic partnership with Guardant Health, Inc. to develop companion diagnostics therapies. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
857 357 7000
Website
https://nuvalent.com
Address
One Broadway, 14th Floor, Cambridge, United States

Latest news

Stocktwits

wizeinvesting Aug 19, 8:30 AM
$NUVL $MBLY $PDYN $ONDS The robotics boom may have lost some of its shine, but the underlying revolution is far from over. As hype fades and valuations reset, a more interesting question emerges: Which companies are actually building the technology that could power the next wave of automation? For a busy investor, this shift can create an opportunity to look beyond flashy headlines and low share prices. Mobileye, Palladyne AI, and Ondas Holdings represent three very different paths into autonomous driving, intelligent machines, drones, and defense technology—each with its own potential, risks, and hurdles to overcome. https://www.wizeinvesting.com/p/no-timing-needed-just-500-a-month-and-time-with-argx
0 replies
outlawinvestor1 Aug 6, 3:14 PM
$NUVB i remain confident in nuvation bio (up 90% since sept 2025) and don't see much of any competition from $NUVL (acquired 50% above sept 2025 level) salvage line approval. $GSK overpaid.
0 replies
55X_ROI_Q1_2026 Aug 3, 4:11 PM
$NUVL $SLS just SLS009 / the secondary asset is worth $5B --- right now -- based on the Phase 2 Expansion Data Published at ASH for AML-MR Patients along w the ongoing Pivotal< Randomized 80 Patient P2B Trial - with PIVOTAL Results Due Next Quarter - that are worth 10x that. Big Pharma is going to Need to see the GPS P3 Data, before Paying ANGIE the $40B / $50B GPs is worth. ... And it won't be Much Longer, given we are Now in AUGUST - 84 Days since the 78th Event, its likely the 80th Occurred Weeks ago / hence the Quiet Period. . . Phase 3 TOP LINE RESULTS are NOW TRULY IMMINENT...
0 replies
SellasgpsCurativeBAT11 Aug 3, 3:48 PM
$SLS$GSK $NUVL BO can happens anytime given GPS overwhelming Breakthrough CURATIVE Data: Ex: GSK closed the Nuvalent, Inc. acquisition on 15th July. Jideytro had FDA approval days later. That timing isn't a credit to fast integration; it's a feature of how these deals actually work that doesn't get discussed enough: the regulatory clock doesn't reset on a change of ownership. The ARROS-1 data was already filed. The review was already running. GSK wasn't buying a bet on whether the science would work, Nuvalent had already derisked that. It was buying a position in an outcome that was, by closing, close to locked in. That's a meaningfully different logic than the one usually applied to biotech M&A. Buying pre-Phase Ill is a science bet. Buying at this stage is a timing and distribution bet, the value is in being the company selling the drug the day it clears, not in the probability that it clears at all. Here we are waiting for data but big pharma due to patent cliff has other plans. ✌️❤️‍🩹🙏
0 replies
SellasgpsCurativeBAT11 Jul 30, 3:13 PM
$RVMD $SLS $GSK $NUVL Buy out can happens anytime given the overwhelming success? Ex: GSK closed the Nuvalent, Inc. acquisition on 15th July. Jideytro had FDA approval days later. That timing isn't a credit to fast integration; it's a feature of how these deals actually work that doesn't get discussed enough: the regulatory clock doesn't reset on a change of ownership. The ARROS-1 data was already filed. The review was already running. GSK wasn't buying a bet on whether the science would work, Nuvalent had already de-risked that. It was buying a position in an outcome that was, by closing, close to locked in. That's a meaningfully different logic than the one usually applied to biotech M&A. Buying pre-Phase Ill is a science bet. Buying at this stage is a timing and distribution bet, the value is in being the company selling the drug the day it clears, not in the probability that it clears at all. Here we are waiting for data but big pharma due to patent cliff has other plans. ✌️🙏❤️‍🩹
0 replies
wyoming2020 Jul 23, 5:18 PM
$NUVL $GSK rectal approval next
0 replies
ConsulHorkos Jul 23, 12:25 AM
$NUVL congrats on your approval post BO
0 replies
SellasgpsCurativeBAT11 Jul 20, 6:10 PM
$SLS $GSK $NUVL GSK just paid $10.6 BILLION. That's what GSK is paying to acquire Nuvalent (NUVL). Big pharmaceuticals are in a buying frenzy with $380 Billion in patent expirations within next 2 years.
1 replies